Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.

Alam N, Gustafson KS, Ladanyi M, Zakowski MF, Kapoor A, Truskinovsky AM, Dudek AZ.

Clin Lung Cancer. 2010 Sep 1;11(5):E1-4. doi: 10.3816/CLC.2010.n.046.

PMID:
20837450
2.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
3.

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.

Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Takahashi K, Yamamoto N.

Cancer Sci. 2011 May;102(5):1032-7. doi: 10.1111/j.1349-7006.2011.01887.x. Epub 2011 Feb 28.

4.

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.

Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T, Imaizumi K, Kume H, Hasegawa Y, Shimokata K, Sekido Y.

Lung Cancer. 2005 Dec;50(3):385-91. Epub 2005 Sep 2.

PMID:
16140420
5.

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.

Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ.

Lung Cancer. 2006 Nov;54(2):201-7. Epub 2006 Sep 7.

PMID:
16956694
6.

Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.

Tokumo M, Toyooka S, Ichihara S, Ohashi K, Tsukuda K, Ichimura K, Tabata M, Kiura K, Aoe M, Sano Y, Date H, Shimizu N.

Lung Cancer. 2006 Jul;53(1):117-21. Epub 2006 May 30.

PMID:
16730855
7.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

8.

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.

Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44.

9.

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.

Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF.

Clin Cancer Res. 2004 Dec 15;10(24):8195-203.

10.

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.

Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T.

Lung Cancer. 2011 Mar;71(3):249-57. doi: 10.1016/j.lungcan.2010.12.008. Epub 2011 Jan 8. Review.

PMID:
21216486
11.

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.

Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, Zhou HS, Guo BQ.

Clin Cancer Res. 2005 Jun 15;11(12):4289-94.

12.

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA.

J Clin Oncol. 2005 Nov 1;23(31):8081-92. Epub 2005 Oct 3.

PMID:
16204011
13.

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T.

Clin Cancer Res. 2006 Oct 1;12(19):5764-9.

14.

Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.

Oh IJ, Ban HJ, Kim KS, Kim YC.

Lung Cancer. 2012 Jul;77(1):121-7. doi: 10.1016/j.lungcan.2012.01.012. Epub 2012 Feb 12.

PMID:
22333554
15.

EGFR polymorphism of the kinase domain in Japanese lung cancer.

Sasaki H, Endo K, Takada M, Kawahara M, Tanaka H, Kitahara N, Matsumura A, Iuchi K, Kawaguchi T, Okuda K, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.

J Surg Res. 2008 Aug;148(2):260-3. doi: 10.1016/j.jss.2007.09.001. Epub 2007 Oct 5.

PMID:
18541260
16.

Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.

Endo K, Sasaki H, Yano M, Kobayashi Y, Yukiue H, Haneda H, Suzuki E, Kawano O, Fujii Y.

Oncol Rep. 2006 Sep;16(3):533-41.

PMID:
16865253
17.

The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.

Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, Tanimoto M, Date H, Gazdar AF, Shimizu N.

Clin Cancer Res. 2005 Feb 1;11(3):1167-73.

18.

Predictors of the response to gefitinib in refractory non-small cell lung cancer.

Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, Ahn SJ, Baek SM, Park CS, Park CM, Kim YI, Lim SC, Park KO.

Clin Cancer Res. 2005 Mar 15;11(6):2244-51.

19.

Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.

Cho D, Kocher O, Lee JC, Tenen DG, Meyerson ML, Janne PA, Halmos B.

J Clin Oncol. 2005 Jan 1;23(1):235-7. No abstract available. Erratum in: J Clin Oncol. 2005 Apr 1;23(10):2444.

PMID:
15625379
20.

Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.

Ushiki A, Koizumi T, Kobayashi N, Kanda S, Yasuo M, Yamamoto H, Kubo K, Aoyagi D, Nakayama J.

Jpn J Clin Oncol. 2009 Apr;39(4):267-70. doi: 10.1093/jjco/hyn155. Epub 2009 Jan 20.

PMID:
19155283

Supplemental Content

Support Center